An overview of automated systems relevant in pharmaceutical salt screening

Drug Discovery Today

Volumn 12, Issue 23-24, 2007, Pages 1046-1053

  Kumar, Lokesh ^a   Amin, Aeshna ^a   Bansal, Arvind K ^a  

^a NATIONAL INSTITUTE OF PHARMACEUTICAL EDUCATION AND RESEARCH NIPER   (India)

Author keywords

[No Author keywords available]

Indexed keywords

CAFFEINE; EPHEDRINE; NAPROXEN; SERTRALINE; SODIUM CHLORIDE; SULFATHIAZOLE; TAMOXIFEN; TRAZODONE;

CRYSTALLIZATION; DRUG DESIGN; DRUG IDENTIFICATION; DRUG INDUSTRY; DRUG RESEARCH; DRUG SCREENING; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; MELTING POINT; RAMAN SPECTROMETRY; REVIEW; SCALE UP; SOLUBILITY; X RAY DIFFRACTION;

AUTOMATION; CHEMISTRY, PHARMACEUTICAL; CHEMISTRY, PHYSICAL; DRUG EVALUATION, PRECLINICAL; PHARMACEUTICAL PREPARATIONS; SALTS;

EID: 36549018122     PISSN: 13596446     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.drudis.2007.08.002     Document Type: Review

References (52)

1. Li M.S., and Kerns E.K. LC/MS applications in drug development. Mass Spectrum Rev. 18 (2000) 187-279
2. Wermuth C.G., and Stahl P.H. Introduction. In: Stahl P.H., and Wermuth C.G. (Eds). Handbook of Pharmaceutical Salts: Properties, Selection and Use (2002), Wiley-VCH 1-7
3. In: Brittain H.G. (Ed). Polymorphism in Pharmaceutical Solids (2002), Marcel Dekker Inc.
4. Datta S., and Grant D.J.W. Crystal structures of drugs: advances in determination, prediction and engineering. Nat. Rev. Drug Discov. 3 (2004) 42-57
5. Anderson B.D., and Conradi R.A. Predictive relationships in the water solubility of salts of a nonsteroidal anti-inflammatory drug. J. Pharm. Sci. 74 (1985) 815-820
6. Bastin R.J., et al. Salt selection and optimization procedures for pharmaceutical new chemical entities. Org. Process Res. Dev. 4 (2000) 427-435
7. Berge S.M., et al. Pharmaceutical salts. J. Pharm. Sci. 66 (1977) 1-19
8. Bhattachar S.N., et al. Solubility: it's not just for physical chemists. Drug Discov. Today 11 (2006) 1012-1018
9. Connor K.M.O., and Corrigan O.I. Preparation and characterisation of a range of diclofenac salts. Int. J. Pharm. 226 (2001) 163-169
10. Raumer V.M., et al. Polymorphism, salts, and crystallization: the relevance of solid-state development. Chem. Today 24 (2006) 41-44
11. Fini A., et al. Factors governing the dissolution of diclofenac salts. Int. J. Pharm. 4 (1996) 231-238
12. Remenar J.F., et al. Salt selection and simultaneous polymorphism assessment via high-throughput crystallization: the case of sertraline. Org. Process Res. Dev. 7 (2003) 990-996
13. Stephenson G.A. Applications of x-ray powder diffraction in the pharmaceutical industry. Rigaku J. 22 (2005) 2-15
14. Morris K.R., et al. An integrated approach to the selection of optimal salt form for a new drug candidate. Int. J. Pharm. 105 (1994) 209-217
15. Morissette S.L., et al. High-throughput crystallization: polymorphs, salts, co-crystals and solvates of pharmaceutical solids. Adv. Drug Deliv. Rev. 56 (2004) 275-300
16. Kojima T., et al. Crystalline form information from multiwell plate salt screening by use of Raman microscopy. Pharm. Res. 23 (2006) 806-812
17. Lowry S., et al. Integrating a Raman microscope into the workflow of a high-throughput crystallization laboratory. J. Assoc. Lab. Automat. 11 (2006) 75-84
18. Hammond R.B., et al. Grid-based molecular modeling for pharmaceutical salt screening: case example of 3,4,6,7,8,9-hexahydro-2H-pyrimido (1,2-a) pyrimidinium acetate. J. Pharm. Sci. 95 (2006) 2361-2372
19. Carlson E.D., et al. Automated integrated forced degradation and drug-excipient compatibility studies. J. Assoc. Lab. Automat. 10 (2005) 374-380
20. Carlson E.D., et al. An integrated high throughput workflow for pre-formulations: polymorph and salt selection studies. Pharmachem 1 (2003) 10-15
21. Barr G., et al. PolySNAP: a computer program for analysing high-throughput powder diffraction data. J. Appl. Cryst. 37 (2004) 658-664
22. Higgins J.D., and Rocco W.L. Pharma preformulation-a stop along the drug development highway. Today's Chemist at Work 12 (2003) 22-26
23. Morissette S.L., et al. Elucidation of crystal form diversity of the HIV protease inhibitor ritonavir by high throughput crystallization. Proc. Natl. Acad. Sci. 100 (2003) 2180-2184
24. Mirmehrabi M., and Rohani S. An approach to solvent screening for crystallization of polymorphic pharmaceuticals and fine chemicals. J. Pharm. Sci. 94 (2005) 1560-1576
25. Gu C.H., et al. Grouping solvents by statistical analysis of solvent property parameters: implication to polymorph screening. Int. J. Pharm. 283 (2004) 117-125
26. Birch M., et al. Towards a PAT-based strategy for crystallization development. Org. Process Res. Dev. 9 (2005) 360-364
27. Carlson, E.D. et al. [Symyx Technologies] Apparatuses and methods for creating and testing pre-formulations and systems for same. USP6939515
28. Gardner C.R., et al. Application of high throughput technologies to drug substance and drug product development. Comput. Chem. Eng. 28 (2004) 943-953
29. Ware E.C., and Lu D.R. An automated approach to salt selection for new unique trazodone salts. Pharm. Res. 21 (2004) 177-184
30. Desrosiers P.J. The potential of preformulation. Mod. Drug Discov. 7 (2004) 40-43
31. Byrn S., et al. Pharmaceutical solids: a strategic approach to regulatory considerations. Pharm. Res. 12 (1995) 945-954
32. Bugay D.E. Characterization of solid-state: spectroscopic techniques. Adv. Drug Deliv. Rev. 48 (2001) 43-65
33. Findlay W.P., and Bugay D.E. Utilization of Fourier transform-Raman spectroscopy for the study of pharmaceutical crystal forms. J. Pharm. Biomed. Anal. 16 (1998) 921-930
34. Carlson, E.D. et al. [Symyx Technologies] Polymorph characterization. EP1467205A1
35. Balbach S., and Korn C. Pharmaceutical evaluation of early development candidates "the 100 mg-approach". Int. J. Pharm. 275 (2004) 1-12
36. Zografi G. States of water associated with solids. Drug Dev. Ind. Pharm. 14 (1988) 1905-1926
37. Ahlneck C., and Zogafi G. The molecular basis of moisture effects on the physical and chemical stability of drugs in the solid state. Int. J. Pharm. 62 (1990) 87-95
38. Callahan J.C. Equilibrium moisture content of pharmaceutical excipients. Drug Dev. Ind. Pharm. 8 3 (1982) 355-369
39. Gift A.D., and Taylor L.S. Hyphenation of Raman spectroscopy with gravimetric analysis to interrogate water-solid interactions in pharmaceutical systems. J. Pharm. Biomed. Anal. 43 (2007) 14-23
40. Lipinski C.A., et al. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Deliv. Rev. 23 (1997) 3-25
41. Kane N.R., et al. A System for dispensing sub-milligram doses of active pharmaceutical powders for early stage solubility assays. J. Assoc. Lab. Automat. 9 (2004) 218-227
42. Dinter C., et al. Automated solubility determination using a customized robotic system and a turbidity probe. J. Assoc. Lab. Automat. 10 (2005) 408-411
43. Tan H., et al. An automated screening assay for determination of aqueous equilibrium solubility enabling SPR study during drug lead optimization. J. Assoc. Lab. Automat. 10 (2005) 364-373
44. Chen T.M., et al. Evaluation of a method for high throughput solubility determination using a multi-wavelength UV plate reader. Comb. Chem. High Throughput Screen. 5 (2002) 575-581
45. Chen X.Q., and Venkatesh S. Miniature device for aqueous and non-aqueous solubility measurements during drug discovery. Pharm. Res. 21 (2004) 1758-1761
46. Fermier A.M., et al. Automation of chemical reaction kinetics and product distribution studies in pharmaceutical development. J. Assoc. Lab. Automat. 7 (2002) 83-88
47. Chandler W., et al. The extended core module robot: a flexible, modular platform for high-throughput development workflows. J. Assoc. Lab. Automat. 10 (2005) 418-422
48. Fermier, A.M. et al. [Ortho McNeil Pharm Inc.] Apparatus for the automation of chemical reaction kinetics studies. WO02077614
49. Di L., et al. Development and application of an automated solution stability assay for drug discovery. J. Biomol. Screen. 11 (2006) 40-47
50. Sims J.L., et al. A new approach to accelerated drug-excipient compatibility testing. Pharm. Dev. Technol. 8 (2003) 119-126
51. Wyttenbach N., et al. Drug-excipient compatibility testing using a high-throughput approach and statistical design. Pharm. Dev. Technol. 10 (2005) 499-505
52. Hilfiker R., et al. Polymorphism - integrated approach from high-throughput screening to crystallization optimization. J. Therm. Anal. Calorim. 73 (2003) 429-440